Skip to main content
SpringerLink
Log in

Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF

Beyond EGFR and VEGF

  • Chapter
Colorectal Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 811 Accesses

Abstract

The advent of molecularly targeted therapies has fundamentally changed anticancer drug development. Advances in molecular oncology have altered scientific paradigms in drug discovery, and preclinical and early clinical drug development. In the current era, selective therapies are now rationally designed to inhibit specific novel targets that are well characterized at the molecular level. Inherent in this approach are new strategies that include testing agents in pharmacogenetically defined populations, analyzing the molecular profile of tumors prior to treatment, and individualizing anticancer therapy for each unique patient. Examples of promising molecular targets for future therapies for treating patients with colorectal cancer include the PI3K/Akt/mTOR signaling pathway and antiangiogenic inhibition, to name just two. This brief review discusses the new challenges and changing paradigms related to developing novel colorectal cancer therapeutics in the age of molecularly targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10(8):789–799.

    Article  PubMed  CAS  Google Scholar 

  2. Ligon BL. Penicillin: its discovery and early development. Semin Pediatr Infect Dis 2004;15(1):52–57.

    Article  PubMed  Google Scholar 

  3. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698–699.

    Article  PubMed  CAS  Google Scholar 

  4. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105(1):3–7.

    Article  PubMed  CAS  Google Scholar 

  5. Heidelberger C. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep 1981;65 Suppl 3:3–9.

    PubMed  CAS  Google Scholar 

  6. Jordan VC. Third annual William L. McGuire Memorial Lecture. “Studies on the estrogen receptor in breast cancer”-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995;36(3):267–285.

    Article  PubMed  CAS  Google Scholar 

  7. Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol 2005;23(23):5374–5385.

    Article  PubMed  CAS  Google Scholar 

  8. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4(4):257–262.

    Article  PubMed  CAS  Google Scholar 

  9. Foukas LC, Shepherd PR. Phosphoinositide 3-kinase: the protein kinase that time forgot. Biochem Soc Trans 2004;32(Pt 2):330–331.

    Article  PubMed  CAS  Google Scholar 

  10. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22(20):4217–4226.

    Article  PubMed  CAS  Google Scholar 

  11. Mende I, Malstrom S, Tsichlis PN, Vogt PK, Aoki M. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 2001;20(32):4419–4423.

    Article  PubMed  CAS  Google Scholar 

  12. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22(14):2954–2963.

    Article  PubMed  CAS  Google Scholar 

  13. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91(8):1420–1424.

    Article  PubMed  CAS  Google Scholar 

  14. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003;3(4):371–377.

    Article  PubMed  CAS  Google Scholar 

  15. Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 2004;25(2):241–248.

    Article  PubMed  CAS  Google Scholar 

  16. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9(6):667–676.

    Article  PubMed  CAS  Google Scholar 

  17. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7(6):561–573.

    Article  PubMed  CAS  Google Scholar 

  18. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436(7052):792.

    Article  PubMed  CAS  Google Scholar 

  19. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3_-kinase, in human colon cancer cells. Clin Cancer Res 2002;8(6):1957–1963.

    PubMed  CAS  Google Scholar 

  20. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004;32(Pt 2):393–396.

    Article  PubMed  CAS  Google Scholar 

  21. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4(9):1349–1357.

    Article  PubMed  CAS  Google Scholar 

  22. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093–1103.

    PubMed  CAS  Google Scholar 

  23. Van Ummersen L, Binger K, Volkman J, et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 2004;10(22):7450–7456.

    Article  PubMed  Google Scholar 

  24. Dancey JE. Molecular targeting: PI3 kinase pathway. Ann Oncol 2004;15 Suppl 4:iv233–239.

    PubMed  Google Scholar 

  25. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16(4):525–537.

    Article  PubMed  CAS  Google Scholar 

  26. Desai AA, Janisch L, Berk LR, et al. A phase I trail of a novel mTOR inhibitor AP23573 adminisered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc Am Soc Clin Oncol 2004;22(14S):3150.

    Google Scholar 

  27. Mita MM, Rowinsky EK, Goldston ML, et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patienst (pts) with refractory or advanced malignancies. Proc Am Soc Clin Oncol 2004;22(14S):3076.

    Google Scholar 

  28. Chawla SP, Sankhala KK, Chua V, et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. Proc Am Soc Clin Oncol 2005;23:9068.

    Google Scholar 

  29. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58–62.

    Article  PubMed  CAS  Google Scholar 

  30. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18(5):991–1006, vii.

    Article  PubMed  Google Scholar 

  31. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90(3):561–565.

    Article  PubMed  CAS  Google Scholar 

  32. Schwartz MA. Integrin signaling revisited. Trends Cell Biol 2001;11(12):466–470.

    Article  PubMed  CAS  Google Scholar 

  33. Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM. Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004;23(53):8659–8672.

    Article  PubMed  CAS  Google Scholar 

  34. Ricart A, Liu G, Tolcher A, et al. A phase I dose-escalation study of anti-α5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors. Eur J Cancer 2004;2(Suppl):52.

    Google Scholar 

  35. Mita MM, Mita AC, Goldston ML, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: results of a phase I study. Proc Am Soc Clin Oncol 2005;23:3082.

    Google Scholar 

  36. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000;6(8):3056–3061.

    PubMed  CAS  Google Scholar 

  37. Eskens F, Dumez H, Verweij J, et al. Phase I and pharmacologic study of EMD 121974, an (((3 and (((5 interin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors. Proc Am Soc Clin Oncol 2000;18:801.

    Google Scholar 

  38. Martin PL, Jiao Q, Cornacoff J, et al. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res 2005;11(19 Pt 1):6959–6965.

    Article  PubMed  CAS  Google Scholar 

  39. Syed SK, Beeram M, Takimoto CH, et al. Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. Proc Am Soc Clin Oncol 2004;22:2028.

    Google Scholar 

  40. Rhee JM, Lee F, Saif MW, et al. Phase II Trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. Proc Am Soc Clin Oncol 2005;23:3654.

    Google Scholar 

  41. Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54(8):1194–1202.

    Article  PubMed  CAS  Google Scholar 

  42. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11(22):7967–7985.

    Article  PubMed  CAS  Google Scholar 

  43. Ku G, Fornage BD, Jin X, Xu M, Hunt KK, Wang LV. Thermoacoustic and photoacoustic tomography of thick biological tissues toward breast imaging. Technol Cancer Res Treat 2005;4(5):559–566.

    PubMed  Google Scholar 

  44. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005;107(2):155–176.

    Article  PubMed  CAS  Google Scholar 

  45. Dracopoli NC. Pharmacogenomic applications in clinical drug development. Cancer Chemother Pharmacol 2003;52 Suppl 1:S57–S60.

    Article  PubMed  CAS  Google Scholar 

  46. Okumura K, Shirasawa S, Nishioka M, Sasazuki T. Activated Ki-Ras suppresses 12-Otetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells. Cancer Res 1999;59(10):2445–2450.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, University of Texas Health Science Center, San Antonio, TX

    Chris Takimoto MD, PhD

  2. Pharmacogenomics Laboratory, University of Texas, San Antonio, TX

    Russell Kruzelock ,PhD

Authors
  1. Chris Takimoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell Kruzelock ,PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

    Leonard B. Saltz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Takimoto, C., Kruzelock, R. (2007). Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF. In: Markman, M., Saltz, L.B. (eds) Colorectal Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-215-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-215-1_15

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-751-8

  • Online ISBN: 978-1-59745-215-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation